Journal article

Targeting MCL-1 in hematologic malignancies: Rationale and progress

Andrew H Wei, Andrew W Roberts, Andrew Spencer, Aaron Seth Rosenberg, David Siegel, Roland B Walter, Sean Caenepeel, Paul Hughes, Zach McIver, Khalid Mezzi, Phuong Khanh Morrow, Anthony Stein

Blood Reviews | CHURCHILL LIVINGSTONE | Published : 2020

Abstract

Myeloid cell leukemia sequence 1 (MCL-1) is an antiapoptotic protein that plays a key role in promoting cell survival in multiple myeloma (MM), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Overexpression of MCL-1 is associated with treatment resistance and poor prognosis; thus, MCL-1 inhibitors are rational therapeutic options for malignancies depending on MCL-1. Several MCL-1 inhibitors have entered clinical trials, including AZD5991, S64315, AMG 176, and AMG 397. A key area of investigation is whether MCL-1 inhibitors will complement the activity of BCL-2 inhibitors, such as venetoclax, and synergistically enhance anti-tumor efficacy when given in combination with other an..

View full abstract

University of Melbourne Researchers

Grants

Awarded by UC Davis Paul Calabresi Career Development Award for Clinical Oncology - National Cancer Institute/National Institutes of Health


Funding Acknowledgements

The authors thank Jesse Potash (Amgen Inc., Thousand Oaks, CA, USA) and Lee Hohaia and Meghan Johnson (Complete Healthcare Communications, LLC, North Wales, PA, USA), whose work was funded by Amgen Inc., for medical writing assistance in the preparation of this manuscript.Supported in part by the UC Davis Paul Calabresi Career Development Award for Clinical Oncology as funded by the National Cancer Institute/National Institutes of Health through grant #5K12-CA138464.